Transfection technologies market to value $1.5 billion by 2026
Growth in the global transfection technologies market will be driven by emerging methods and the increasing prevalence of chronic diseases over the next five years.
According to a market research report, the global transfection technologies market is expected to reach a value of $1.5 billion by 2026, owing to the increasing prevalence of cancer and various chronic lifestyle diseases and the widespread adoption of reagent-based transfection methods.
The report suggests that the market will achieve a compound annual growth rate of 8.44 percent between 2021 and 2026.
Transfection technologies such as CRISPR-Cas are used to artificially introduce nucleic acid, such as DNA, RNA or oligonucleotides, into cells, modifying their physical, chemical and/or biological properties. Various methods exist, including co-transfection, electroporation, cationic lipid transfection and in vivo transfection.
Transfection is commonly used for genomic studies that include gene expression, screening, RNA interference and in vivo research, along with the bioproduction of viruses and proteins.
According to the report, major factors promoting the growth of the global transfection technologies market include the increasing prevalence of cancer and various chronic lifestyle diseases, and the adoption of reagent-based methods for transfection. Reagent-based methods are typically less complicated and more cost effective than traditional transfection methods, wrote the study authors. Additionally, instrument-based methods are gaining traction, with examples including microinjection and laserfection.
The research also shows that technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor. In addition, research in gene transfer is mainly performed under in vivo conditions for the development of novel therapeutic drugs and various other applications.
Other factors driving market growth include increasing investments by both government and private organisations to develop large scale transfection facilities, along with extensive R&D activities in the field of protein therapeutics.
Key players in the global transfection technologies market are Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation and Thermo Fisher Scientific Inc.